Top Headlines in AMD/Retina: Subretinal drusenoid deposits and CVD risk; combo treatment for maculopathy; and more
In this edition, Iveric Bio is given exclusive permission to develop, commercialize new formulations of Zimura; subretinal drusenoid deposits linked with cardiovascular disease; subcutaneous elamipretide may improve visual function in geographic atrophy; and more.
Read the full coverage here:
Iveric Bio given exclusive permission to develop, commercialize new formulations of Zimura
Subretinal drusenoid deposits linked with cardiovascular disease
Subcutaneous elamipretide may improve visual function in geographic atrophy
Combination technique useful for treating myopic traction maculopathy
Insufficient treatment common among patients with wet AMD
References:
Barikian A, et al. Characteristics and outcomes of patients with nAMD managed in US routine clinical practice: An analysis of the IRIS Registry database. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Chew FM, et al. Scleral imbrication with combined pars plana vitrectomy and foveal sparing ILM peel as a useful surgical modality in treating myopic traction maculopathy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Heier JS. ReCLAIM-2 study results: A phase 2 study of elamipretide safety & efficacy in geographic atrophy. Presented at: American Society of Retina Specialists annual meeting; July 13-16, 2022; New York.
Thompson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460.
Collapse
Read more about
